Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Ibezapolstat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Acurx Starts Ibezapolstat Trial In Recurrent CDI
    Acurx Starts Ibezapolstat Trial In Recurrent CDI

    09 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acurx-announces-new-ibezapolstat-clinical-trial-program-in-patients-with-recurrent-cdi-that-has-the-potential-to-shift-the-paradigm-of-treatment-and-prevention-of-c-difficile-infection-302707476.html

    PR NEWSWIRE
    09 Mar 2026
    Share Share
    Acurx Publishes Unique DNA Pol IIIC Targeting In Nature
    Acurx Publishes Unique DNA Pol IIIC Targeting In Nature

    10 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acurx-announces-publication-in-the-nature-communications-scientific-journal-documenting-its-unique-targeting-of-dna-pol-iiic-gram-positive-priority-pathogens-302608275.html

    PR NEWSWIRE
    10 Nov 2025
    Share Share
    Acurx Data Shows Gut-Selective Effect of DNA pol IIIC Antibiotics
    Acurx Data Shows Gut-Selective Effect of DNA pol IIIC Antibiotics

    28 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acurx-announces-new-data-on-its-dna-pol-iiic-inhibitor-antibiotics-demonstrating-a-potential-class-effect-of-gut-microbiome-selectivity-presented-at-idweek-2025-scientific-conference-302593922.html

    PR NEWSWIRE
    28 Oct 2025
    Share Share
    Acurx Gets EMA Positive Opinion on PIP for Ibezapolstat in CDI
    Acurx Gets EMA Positive Opinion on PIP for Ibezapolstat in CDI

    30 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acurx-announces-positive-opinion-from-ema-on-pediatric-investigation-plan-for-ibezapolstat-use-in-children-with-c-difficile-infection-302570470.html

    PR NEWSWIRE
    30 Sep 2025
    Share Share
    Acurx Publishes Data On Ibezapolstat's Gut Microbiome Effects
    Acurx Publishes Data On Ibezapolstat's Gut Microbiome Effects

    03 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acurx-announces-publication-of-nonclinical-in-vivo-data-differentiating-ibezapolstats-gut-microbiome-effects-from-other-anti-cdi-antibiotics-302386442.html

    PR NEWSWIRE
    03 Mar 2025
    Share Share
    Acurx publishes positive results on Ibezapolstat for CDI.
    Acurx publishes positive results on Ibezapolstat for CDI.

    24 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acurx-announces-publication-of-positive-results-from-an-in-silico-study-predicting-the-microbiome-restorative-potential-of-ibezapolstat-in-the-treatment-of-cdi-302382681.html

    PR NEWSWIRE
    24 Feb 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.